These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 28723227

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC, Fiske K, Lyne A.
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [Abstract] [Full Text] [Related]

  • 24. Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study.
    Toren P, Weizman A, Ratner S, Cohen D, Laor N.
    J Clin Psychiatry; 2005 Apr; 66(4):499-503. PubMed ID: 15816793
    [Abstract] [Full Text] [Related]

  • 25. Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study.
    Lyon GJ, Samar S, Jummani R, Hirsch S, Spirgel A, Goldman R, Coffey BJ.
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):623-33. PubMed ID: 20035580
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Cutler AJ, Brams M, Bukstein O, Mattingly G, McBurnett K, White C, Rubin J.
    J Am Acad Child Adolesc Psychiatry; 2014 Oct; 53(10):1092-101. PubMed ID: 25245353
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea.
    Kim BN, Lee CB, Hwang JW, Shin MS, Cho SC.
    J Child Adolesc Psychopharmacol; 2005 Apr; 15(2):318-24. PubMed ID: 15910216
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A double-blind, placebo-controlled trial of ω-3 fatty acids in Tourette's disorder.
    Gabbay V, Babb JS, Klein RG, Panzer AM, Katz Y, Alonso CM, Petkova E, Wang J, Coffey BJ.
    Pediatrics; 2012 Jun; 129(6):e1493-500. PubMed ID: 22585765
    [Abstract] [Full Text] [Related]

  • 36. A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette's Syndrome.
    Bloch MH, Landeros-Weisenberger A, Johnson JA, Leckman JF.
    J Neuropsychiatry Clin Neurosci; 2021 Jun; 33(4):328-336. PubMed ID: 34340527
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A double-blind, sham-controlled, trial of home-administered rhythmic 10-Hz median nerve stimulation for the reduction of tics, and suppression of the urge-to-tic, in individuals with Tourette syndrome and chronic tic disorder.
    Maiquez BM, Smith C, Dyke K, Chou CP, Kasbia B, McCready C, Wright H, Jackson JK, Farr I, Badinger E, Jackson GM, Jackson SR.
    J Neuropsychol; 2023 Sep; 17(3):540-563. PubMed ID: 37133932
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.